Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection
Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020,
to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly
assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500
/12 h for 7 days, or a control group with no antibiotics, All three groups received only
symptomatic treatment for control of fever and cough